Videos

Neurology News Network. for the week ending January 11, 2025. [WATCH TIME: 4 minutes]

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry provided a clinical overview of preclinical research identifying a new receptor for nerve growth factor that plays an important role in pain signaling. [WATCH TIME: 4 minutes]

The senior vice president of research at The ALS Association discussed the need for standardizing ALS diagnosis across institutions to reduce delays and ensure timely treatment. [WATCH TIME: 4 minutes]

The senior vice president of research at The ALS Association provided commentary on recently published research that found specialists to diagnose ALS twice as fast as general neurologists. [WATCH TIME: 4 minutes]

The professor in the department of clinical pharmacy and neurology at the University of Colorado reflected on the significance of peer recognition, the evolution of MS clinics, and the importance of staying engaged in professional contributions. [WATCH TIME: 6 minutes]

The postdoctoral research assistant at Charité University Berlin discussed advances in diagnostic criteria and 7-Tesla MRI imaging, highlighting a previously overlooked overlap between anti-N-methyl-D-aspartate receptor encephalitis and multiple sclerosis. [WATCH TIME: 5 minutes]

Panelists discuss how in multiple sclerosis (MS) treatment, clinicians must strategically evaluate disease progression, considering within-class or mechanism-of-action switches. Comprehensive monitoring, personalized approaches, and proactive management are crucial for optimizing patient outcomes and minimizing long-term neurological disability.

The neurologist and sleep disorder specialist at Allegheny Health Network provided an in-depth exploration of the current advancements and future directions in narcolepsy drug development. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending January 4, 2025. [WATCH TIME: 4 minutes]

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about the shift in multiple sclerosis diagnostics from rigid classification systems to a dynamic, spectrum-based approach focused on biological phenotyping. [WATCH TIME: 5 minutes]

Panelists discuss how clinicians can evaluate cognitive health using neuroimaging, cerebrospinal fluid (CSF)/blood biomarkers, and comprehensive assessments. Understanding concepts like cognitive progressive irreversible reductions in activity (PIRA) and focusing on multifaceted interventions—including lifestyle modifications, early detection, and personalized strategies—can help maintain cognitive wellness and mitigate decline.

Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending December 21, 2024. [WATCH TIME: 4 minutes]

Tamara Kaplan, MD, introduces a new video series highlighting the scope and treatment of neurogenic bladder.

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

The chief executive officer and cofounder of Amprion provided clinical insight on the novelty behind the company’s synuclein seed amplification assay and how it may better differentiate synucleinopathies diseases like MSA. [WATCH TIME: 8 minutes]

A duo from Child Neurology Foundation discussed advancing care, providing education for all stakeholders, and offering direct support to families, clinicians, and caregivers navigating neurological conditions for pediatric patients. [WATCH TIME: 5 minutes]

The professor of neurology at NYU Grossman School of Medicine discussed a pioneering study using long seizure episodes to optimize treatment devices and identify effective antiseizure drugs in epilepsy care. [WATCH TIME: 2 minutes]

A duo of experts talked about 2 studies presented at AES 2024 that used the Pediatric Epilepsy Research Consortium genetics database to study factors influencing latency in genetic testing and drug-resistant epilepsy. [WATCH TIME: 5 minutes]

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Research Consortium review on the need for standardized socio-demographic data and better follow-up for at-risk infants. [WATCH TIME: 5 minutes]

Panelists discuss how disease-modifying therapies (DMTs) like dimethyl fumarate, fingolimod, and cladribine demonstrate potential blood-brain barrier penetration, offering neuroprotective mechanisms. While these therapies show promise in mitigating cognitive decline, their impacts vary, highlighting the complex interplay among neuroinflammation, immune modulation, and cognitive preservation in multiple sclerosis management.

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

Panelists discuss how in managing multiple sclerosis (MS), clinicians must adopt a comprehensive approach to progressive irreversible reductions in activity (PIRA) that prioritizes early detection, transparent communication, and patient empowerment. By integrating regular cognitive assessments, providing compassionate and clear explanations, and emphasizing proactive management strategies, physicians can help patients navigate the complex cognitive landscape of MS, ultimately preserving quality of life and fostering patient resilience in the face of neurological challenges.

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

The director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]

The pediatric epileptologist at Johns Hopkins Medicine discussed common triggers and potential preventive measures of status epilepticus in LGS, as well as the importance of involving families and caregivers. [WATCH TIME: 4 minutes]